Cargando…
SGLT inhibitor adjunct therapy in type 1 diabetes
Non-insulin adjunct therapies in type 1 diabetes have been proposed as a means of improving glycaemic control and reducing risk of hypoglycaemia. Evidence to support this approach is, however, scant and few pharmacological agents have proved effective enough to become part of routine clinical care....
Autores principales: | McCrimmon, Rory J., Henry, Robert R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133151/ https://www.ncbi.nlm.nih.gov/pubmed/30132030 http://dx.doi.org/10.1007/s00125-018-4671-6 |
Ejemplares similares
-
Hypoglycemia in Type 1 Diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2010) -
Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab
por: McNeilly, Alison D., et al.
Publicado: (2018) -
Consequences of recurrent hypoglycaemia on brain function in diabetes
por: McCrimmon, Rory J.
Publicado: (2021) -
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015) -
Remembrance of things past: The consequences of recurrent hypoglycaemia in diabetes
por: McCrimmon, Rory J.
Publicado: (2022)